Department of Youth Affairs to host BRICS Youth Council Meeting (See 'Corp Brief') IBC - Only crystallised claims as on effective date are payable on pro-rata basis from designated Operational Creditors Settlement Amount: SC (See 'Legal Desk') RDDBFI - Borrowers cannot cherry-pick figures from bank certificates while ignoring standard accounting treatment of interest after NPA classification: SC (See 'Legal Desk') IPR - Holding subsequent trademark registration does not override prior court injunction protecting visual get-up: HC (See 'Legal Desk') PSB Confluence 2026 - deposit mobilisation, banking for youth & investment cycles on agenda (See 'Corp Brief') A&C - Continuation of arbitration proceedings against some guarantors while statutory interim moratorium u/s 96 of IBC is in effect regarding 'debt' violates fundamental policy of Indian law: HC (See 'Legal Desk') IBC - Rights issue that does not comply with the mandatory timing and procedural requirements under company law, and which reduces majority shareholders into minority and transfers control, constitutes oppression: NCLT (See 'Legal Desk') DFS highlights mechanism for Timely Redressal of Insurance Policyholders' Grievances (See 'Corp Brief') CCRAS-NIIMH signs MoU with Sevadhi Museum and Indological Research Institute for Digitization (See 'Corp Brief') IBC - Second proviso to Rule 30(9) of Companies (Incorporation) Rules, 2014, acts as mandatory statutory bar, which prevents Regional Director from allowing shifting of registered office while appeal against resolution plan is pending: HC (See 'Legal Desk') Over 2 Lakh Villages, Now 'Har Ghar Jal' Certified (See 'Corp Brief') Companies Act - Assets of a company belong to the entity and its creditors, not its shareholders; transfer of company assets seemingly to place them beyond creditors' reach is impermissible: HC (See 'Legal Desk') MSDE convenes India-Japan Stakeholder Consultation to strengthen skilling (See 'Corp Brief') Competition law - Dealership termination, even if commercially harsh, does not by itself become competition law violation unless there is material showing an anti-competitive agreement causing dominance and abuse: CCI (See 'Legal Desk') Naidu flags off Tiranga Rally under Har Ghar Tiranga Campaign 2026 (See 'Corp Brief') IBC - EPC contract cannot be said to be frustrated by efflux of time merely because works have been suspended due to non-payment: SC (See 'Legal Desk') Capital Market - Trading while in possession of Unpublished Price Sensitive Information automatically triggers insider trading liability: SC (See 'Legal Desk') States recognised for Strong Performance in Anemia Mukt Bharat Abhiyaan (See 'Corp Brief') Misc - Winding-up proceeding and civil suit for recovery of money are distinct and independent remedies, and initiation of one does not impact limitation for other: SC (See 'Legal Desk') Patents - Invoking common general knowledge as basis for rejecting patent application without identifying & substantiating source of such knowledge is impermissible in a quasi-judicial order u/s 15 of the Act: HC (See 'Legal Desk') Gaj Gaurav Awards 2026 conferred for Exemplary Contributions to Elephant Conservation (See 'Corp Brief') IPR - In infringement action u/s 29(2)(b) of Trade Marks Act, where marks are similar but not identical, burden lies strictly on plaintiff to establish that similarity is likely to cause confusion: HC (See 'Legal Desk') Competition - Business model of online food delivery inherently differs from direct restaurant sales - price differential between two does not per se establish abusive conduct per the Competition Act: CCI (See 'Legal Desk') Tete-a-tete around AI in banking sector often begins with algorithms (See CORP EINSICHT)

Print

MoS reaffirms India's commitment to global pharmaceutical standardization

Published: Feb 06, 2025

By TIOLCorplaws News Service

NEW DELHI, FEB 06, 2025: UNION Minister of State for Health and Family Welfare, Anupriya Patel delivered the keynote address at the 15th International Meeting of World Pharmacopoeias (IMWP), hosted by the Indian Pharmacopoeia Commission (IPC) under the aegis of the Ministry of Health and Family Welfare, Government of India, in collaboration with the World Health Organization (WHO), here today. The meeting brought together global pharmacopoeial leaders, regulatory authorities, and industry stakeholders to deliberate on key issues related to pharmaceutical standards and harmonization.

Addressing the gathering, Patel reaffirmed India's commitment to global pharmaceutical standardization and regulatory convergence. She highlighted India's role as the "Pharmacy of the World" and emphasized the importance of ensuring access to high-quality medicines globally. She stated that the IMWP serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization.

On this occasion, the Union Minister also released the IPC Newsletter 2024 and a special IPC video film, which showcase India's advancements in pharmacopoeial science and the Commission's efforts in ensuring high-quality pharmaceutical standards. The video film can be accessed at the following link: https://www.youtube.com/watch?v=MCdAZodvOSM .

Punya Salila Srivastava, Secretary, Ministry of Health and Family Welfare, underscored the significance of global partnerships in strengthening pharmaceutical quality standards. She reiterated India's efforts in aligning regulatory frameworks with international best practices and ensuring the availability of safe and effective medicines worldwide.

Dr. Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director, IPC, and Drugs Controller General (India), highlighted IPC's contributions in setting global benchmarks in pharmacopoeial science. He elaborated on IPC's initiatives, including the IP Online platform, which enhances accessibility and usability of Indian Pharmacopoeia standards. He emphasized the role of scientific advancements and regulatory cooperation in shaping global pharmaceutical standards.

Dr. Roderico H. Ofrin, WHO Representative to India, commended India's leadership in pharmacopoeial standard-setting and emphasized the importance of regulatory harmonization in ensuring patient safety and public health.

The 15th IMWP is set to facilitate discussions on key focus areas, including:

- Updates on recommendations from the 14th IMWP and review of progress on harmonization initiatives.

- Emerging issues in impurity assessment (Q3) and the implications of ICH Q6 guidelines on pharmacopoeial monograph specifications.

- Defining the IMWP Charter to establish a long-term governance structure for the forum.

- Enhancing collaboration among global pharmacopoeias and regulatory bodies, with updates from the Pharmacopoeial Discussion Group (PDG).

- Promotion of environmental sustainability in pharmacopoeial practices and pharmaceutical manufacturing standards.

- Finalization of reports for the 15th IMWP and preparatory discussions for the 16th IMWP.

The deliberations during the IMWP will reinforce the role of pharmacopoeias in ensuring the quality, safety, and efficacy of medicines. The outcomes of the meeting will guide future collaborations in standard-setting and regulatory harmonization.

The 15th IMWP, which commenced today, will conclude on 7th February 2025. The discussions held over these three days will set the stage for further strengthening global pharmacopoeial cooperation and enhancing pharmaceutical quality assurance.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.